Protein disulfide isomerases (PDIs) are essential enzymes that facilitate the proper folding of proteins and maintain protein quality within the endoplasmic reticulum. Dysregulation of PDIs has been correlated with numerous disorders, including cancer and rheumatoid arthritis (RA). E64FC26 (EFC), a small molecule that inhibits a wide range of PDI family members, has shown promise as a therapeutic agent in oncology. However, its effects on RA have not yet been studied. This research investigates the efficacy of EFC as a potential treatment for RA.

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response in the region changes, researchers from Berlin and Heidelberg report in Science Immunology. The detailed insights into cancer progression could advance diagnostics and treatment.

BUFFALO, NY - February 10, 2025 – A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation."

Recently, Insilico Medicine (“Insilico”) announces that the team, with the support of its generative chemistry engine, has developed a novel and highly selective FGFR2/3 dual inhibitor, which maintains efficacy against resistance mutations, shows potency in gastric cancer animal model, and demonstrates a more favorable safety profile compared to existing FGFR inhibitors. The findings have been published in the Journal of Medicinal Chemistry (JMC, IF=7.2)

Professor Woo Young Jang (Department of Orthopedic Surgery, Korea University Anam Hospital) recently won the best paper award at the 2024 fall academic conference of the Korean Musculoskeletal Tumor Society. This award recognizes the outstanding results and academic value of the research led by Professor Jang.